One2Treat patented software was used by both clinicians and breast cancer patients’ representatives in Italy and Portugal, enabling to foster more effective, patient-centered discussions. The software provided personalized benefit-risk assessments directly from clinical trial data, prioritizing the most relevant outcomes to each patient. Facilitating this shared decision-making process is instrumental to improve both treatment acceptance and adherence.